Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 0.83 |
| ▸ | JAK1 | P23458 | 20/20 | 0.83 |
| ▸ | JAK3 | P52333 | 20/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1369154 | 0.95 | JAK2 (0.88) | JAK2JAK1JAK3 | |
| SCHEMBL1371501 | 0.91 | JAK3 (0.91) | JAK2JAK1JAK3 | |
| SCHEMBL1369619 | 0.91 | JAK3 (1.00) | JAK2JAK1JAK3 | |
| SCHEMBL1369953 | 0.91 | JAK3 (1.00) | JAK2JAK1JAK3 | |
| SCHEMBL1369862 | 0.89 | JAK3 (0.77) | JAK2JAK1JAK3 | |
| SCHEMBL1369480 | 0.89 | JAK3 (0.79) | JAK2JAK1JAK3 | |
| SCHEMBL1369646 | 0.88 | JAK3 (0.66) | JAK2JAK1JAK3 | |
| SCHEMBL15755613 | 0.87 | JAK3 (0.76) | JAK2JAK1JAK3 | |
| SCHEMBL15755611 | 0.87 | JAK3 (0.76) | JAK2JAK1JAK3 | |
| SCHEMBL1370677 | 0.86 | JAK3 (1.00) | JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | claimed |
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, JAK2 | JAK2 3/4885JAK1 5/4885JAK3 7/4885 |
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK2 | JAK2 3/4885JAK1 5/4885JAK3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.